A healthier gut may be key to cancer care
A Healthier Gut May Be Key to Cancer Care
A healthier gut may be key – In the early 1990s, Dr. Marcel van den Brink, a rising expert in blood cancers like leukemia, encountered a critical challenge in his work: the delicate process of reconstructing a patient’s immune system through allogenic hematopoietic cell transplants. This procedure, which involves wiping out the existing immune system with powerful chemotherapy and replacing it with donor cells, left patients highly susceptible to infections during the recovery period. At the time, the risk of complications, including graft-versus-host disease where transplanted cells attack the body, was alarmingly high, with roughly a quarter of patients succumbing to such issues. Despite meticulous precautions—such as isolating patients in sterile environments and administering broad-spectrum antibiotics—the outcome remained uncertain, prompting van den Brink and his peers to reconsider their approach.
The Microbiome’s Emergence in Cancer Research
Van den Brink’s insights led to a pivotal shift in the field. He and his colleagues began to realize that the aggressive treatments they had long relied on were causing unintended harm. “We were causing a lot of collateral damage with our aggressive treatment,” he noted, highlighting the need to protect the body’s natural defenses rather than destroy them. This revelation sparked a new era in cancer care, linking the gut microbiome to immune function. The microbiome, the community of microorganisms residing in the digestive tract, has since become a focal point for researchers exploring how it influences disease outcomes and treatment efficacy.
The importance of this connection was underscored at a recent research symposium in California. US Health and Human Services Secretary Robert F. Kennedy Jr. addressed the gathering at the City of Hope Cancer Center in Duarte, where van den Brink was named president in 2023. The event, titled “The Next Frontier of Cancer Prevention and Care,” featured groundbreaking insights from Dr. Jay Bhattacharya, director of the National Institutes of Health. Bhattacharya described the latest findings as “mind-blowing,” emphasizing the microbiome’s potential to revolutionize how we treat cancer. The American Society of Clinical Oncology has since cataloged nearly 100 studies examining ways to manipulate the gut microbiome, from probiotics to dietary interventions, to enhance therapeutic outcomes.
Probiotics in Late-Phase Trials
One such trial is currently underway at the University Hospitals Seidman Cancer Center in Cleveland, where a kidney cancer patient will become the first to receive CBM588, a probiotic strain of Clostridium butyricum, as part of a late-phase study. This multicenter research aims to determine whether probiotics can amplify the effectiveness of immunotherapy, a treatment that leverages the body’s immune system to combat cancer. Patients will take capsules of CBM588 alongside their standard immunotherapy regimens, with results expected to shape future treatment protocols.
CBM588, already a popular supplement in Japan, has been used for decades to address gastrointestinal issues. Its potential in cancer care is now being tested in the US through studies funded by the National Cancer Institute. Earlier small-scale trials have hinted at its benefits, including improved outcomes for patients with renal cell carcinoma who received immune-based therapies. Dr. Pedro Barata, one of the principal investigators on the new trial, expressed confidence in the approach. “We’re hoping to change the standard of care,” he said, underscoring the transformative hopes surrounding microbiome research.
From Animal Farming to Human Health
The interest in gut microbes has roots in unexpected places. Dr. Sumanta Pal, a co-investigator on the Cleveland trial and lead researcher at City of Hope in Los Angeles, first became intrigued over a decade ago. His curiosity was piqued by conversations with Dr. Paul Frankel, a biostatistician at the same institution, who shared observations from the livestock industry. Farmers had noticed that maintaining a healthy gut microbiome in animals could reduce the need for frequent cleaning, allowing them to thrive without excessive intervention. “If their chickens are [healthy and growing well], they’ll limit how often they clean the litter when they put in new chickens,” Frankel explained, drawing a parallel between animal health and human immunity.
These insights inspired Pal to explore the microbiome’s role in cancer treatment. He noted that many animals, including pigs, are routinely given prebiotics like inulin to support their gut bacteria. This fiber-rich supplement helps foster the growth of beneficial microorganisms, a practice that has now gained traction in human medicine. The symposium in California brought together scientists and clinicians to discuss how these principles could be applied to cancer care, marking a turning point in understanding the gut’s role as a therapeutic target.
Immunotherapy and the Gut Microbiome
Immunotherapy, a cornerstone of modern cancer treatment, relies on the body’s immune system to identify and destroy malignant cells. However, its success depends on the microbiome’s ability to modulate immune responses. Researchers now believe that a balanced gut microbiome can enhance the effectiveness of these treatments by improving the immune system’s ability to recognize and attack cancer cells. This connection has led to a surge in clinical trials, with CBM588 being one of the most promising candidates. Over the next few years, nearly 700 individuals with advanced renal cell carcinoma will participate in the study, providing valuable data on the probiotic’s impact.
The implications of this research extend beyond individual treatments. By understanding how gut bacteria interact with the immune system, scientists hope to develop personalized approaches that reduce complications and improve survival rates. Van den Brink, reflecting on his journey, acknowledged the field’s evolution. “It’s not just about wiping out the immune system anymore,” he said, “but about nurturing the right balance to fight cancer more effectively.” This philosophy is now driving innovations in transplant medicine, immunotherapy, and even preventive care.
As the trials progress, the microbiome’s role in cancer care continues to gain momentum. The collaboration between human and animal studies has revealed that the same principles governing gut health in livestock may apply to humans. This cross-disciplinary approach is not only expanding our knowledge but also offering new tools to combat some of the deadliest diseases. The future of cancer treatment, van den Brink suggested, may hinge on a simple yet profound truth: the health of our gut is intrinsically linked to the strength of our immune system.
Challenges and Opportunities Ahead
While the potential of microbiome research is vast, challenges remain. Scientists must determine the optimal strains, dosages, and delivery methods to maximize therapeutic benefits. Additionally, the variability of individual microbiomes complicates efforts to create one-size-fits-all solutions. Yet, these obstacles are being addressed through rigorous studies and collaborative efforts. The upcoming trial at the Seidman Cancer Center represents a significant step forward, offering a glimpse into how probiotics might one day become a standard component of cancer therapy.
The shift in focus from sterile environments to microbiome-enriched care signals a broader transformation in medicine. Where once patients were shielded from all germs, they are now being encouraged to cultivate a diverse gut microbiota. This change reflects a growing awareness that the immune system is not an isolated entity but a complex ecosystem shaped by the trillions of microbes within us. As the field matures, it promises to redefine not only how we treat cancer but also how we approach health and disease prevention on a global scale.